T3P-1127

T3P-1127 is a recombinant live bacterial product (LBP) developed by T3 Pharmaceuticals AG. It is designed as an immuno-oncology therapeutic agent targeting neoplasms (cancers). The drug utilizes a platform based on engineered live Yersinia enterocolitica bacteria to deliver bioactive proteins directly into cancer cells and the tumor microenvironment, aiming to modulate immune responses while sparing healthy tissues. This approach allows for the potential delivery of multiple immune-modulatory proteins in one agent, enabling combination immunotherapy strategies within a single treatment. The mechanism involves modulation of Toll-like receptors (TLR), which are part of the innate immune system and play roles in cancer immunity. T3 Pharmaceuticals AG originally developed this drug, which remains in preclinical development stages as of 2025.

Other names

T3P-1127T-3P-1127T 3P-1127